Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
